Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Manual for Tracking down the Nearby Business sectors and Marketplaces01.01.1 - 2Ukraine Now Using Drone Boats To Attack Russian Riverine Targets26.12.2025
- 3Involved Vehicles for Seniors: Track down the Best Picks for Solace and Unwavering quality25.09.2023
- 4Unwind: Four Extraordinary Spa Resorts On the planet06.06.2024
- 5Sanofi to acquire hepatitis B vaccine maker Dynavax for $2.2 billion24.12.2025
- Blue Origin safely launches wheelchair user to space and back
- Flourishing in a Cutthroat Work Market: Vocation Methodologies
- The Most Enrapturing Authentic Milestones to Visit
- This widow influencer is using jokes to cope after her husband's death. It's OK if people don't get it.
- Figure out How to Analyze Medical attendant Compensation Patterns Across Different Specializations
- The hunt for dark matter: a trivia quiz
- My Excursion to Monetary Autonomy: Awesome ways to save cash
- Volcanic eruption led to the Black Death, new research suggests
- Careful Nurturing: Techniques for Bringing up Tough Children
